BiotechTube

Ceftazidime - Avibactam ( CAZ-AVI) + Doripenem + Either switch to oral therapy: 500 mg of Ciprofloxacin (oral) + or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis

Conditions

Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis

Trial Timeline

Oct 1, 2012 → Aug 1, 2014

NCT ID
NCT01595438

About Ceftazidime - Avibactam ( CAZ-AVI) + Doripenem + Either switch to oral therapy: 500 mg of Ciprofloxacin (oral) + or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)

Ceftazidime - Avibactam ( CAZ-AVI) + Doripenem + Either switch to oral therapy: 500 mg of Ciprofloxacin (oral) + or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral) is a phase 3 stage product being developed by Pfizer for Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01595438. Target conditions include Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis.

What happened to similar drugs?

4 of 20 similar drugs in Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis were approved

Approved (4) Terminated (3) Active (15)
✅Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
✅Daptomycin + VancomycinMerckApproved
✅MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
✅Co-artemetherNovartisApproved
🔄HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placeboJiangsu Hengrui MedicinePhase 3
🔄Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3
🔄CXA-201 and metronidazole + MeropenemMerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01595438Phase 3Completed
NCT01599806Phase 3Completed

Competing Products

20 competing products in Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis

See all competitors
ProductCompanyStageHype Score
ZY19489 + Ferroquine (FQ) + PlaceboZydus LifesciencesPhase 1
36
HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placeboJiangsu Hengrui MedicinePhase 3
47
HRS -8427 + Imipenem and Cilastatin SodiumJiangsu Hengrui MedicinePhase 2
31
Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3
40
Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
35
CXA-201 and metronidazole + MeropenemMerckPhase 3
40
CXA-101 + CeftazidimeMerckPhase 2
35
Ceftolozane/Tazobactam + MeropenemMerckPhase 2
35
Imipenem+Cilastatin/RelebactamMerckPhase 3
40
Daptomycin + VancomycinMerckApproved
35
CXA-101/ tazobactam and metronidazole + meropenem plus saline placeboMerckPhase 2
35
CXA-201 + LevofloxacinMerckPhase 3
40
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for MetronidazoleMerckPhase 2
35
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
43
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 WeeksMerckPhase 3
40
KLU156 + CoartemNovartisPhase 3
40
LYS228 + Standard of care therapyNovartisPhase 2
27
Artemether-lumefantrine (COA566)NovartisPhase 2/3
38
INE963NovartisPhase 2
35
KAE609 + SoC (Coartem) + KLU156NovartisPhase 2
35